For more information, please visit www.cel-sci.com.
Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
When used in this report, the words "intends," "believes," "anticipated", “plans” and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2011. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|THREE MONTHS ENDED DECEMBER 31, 2011 AND 2010|
|GRANT INCOME AND OTHER||$||5,024||$||662,818|
Research and development (excluding R&D depreciation of $114,612 and $116,191 respectively, included below)
|Depreciation and amortization||138,425||141,147|
|General & administrative||1,853,690||1,573,277|
|Total operating expenses||4,448,300||4,978,852|
|GAIN (LOSS) ON DERIVATIVE INSTRUMENTS||956,470||(1,946,395||)|
|ISSUANCE OF ADDITIONAL SHARES||(250,000||)||-|
|MODIFICATIONS OF WARRANTS||(325,620||)||-|
|NET LOSS AVAILABLE TO COMMON SHAREHOLDERS||$||(4,156,833||)||$||(6,250,952||)|
|NET LOSS PER COMMON SHARE|
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING